Skip to main content
Caplight Logo









Novasenta

Novasenta

Private
Pittsburgh, PennsylvaniaHealthcare & Life Scienceshttps://novasenta.com/

Last Round

Series B

Feb 5, 2024

Est. Valuation

$78M

Total Funding Raised

$75M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Novasenta is a biotechnology company that develops innovative immuno-oncology therapeutics and utilizes a machine-learning platform to discover potential drug targets within the tumor microenvironment, aiming to provide safer and more effective cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverycancer immunotherapybiotech startuptumor microenvironmentprecision medicinecomputational biologytarget identificationtherapeutic pipelinepreclinical researchdrug developmentai drug discoverybiotechpharma partneringin silico discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Novasenta Comparables

Compare Novasenta with similar companies based on industry and business-model similarity.

Novasenta comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coherus BioSciences Inc
81%
Asher Biotherapeutics
79%
NextCure Inc
76%

Novasenta Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 5, 2024
Series AJul 29, 2022
SeedAug 23, 2021

Novasenta Investors

Notable investors and investment history

Novasenta investors
InvestorRounds
UPMCSeries A
UPMC EnterprisesSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 43% to 2,029.

  • Feb 5, 2024

    $15M round closed.

Novasenta Filings

Explore SEC and related filing metadata, where available.

Novasenta filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Novasenta's valuation, stock price, and market status.

Is Novasenta a public or private company?

Novasenta is a private company.

What is the current stock price of Novasenta?

Novasenta is a private company with no public stock price. No recent secondary market data is available.

How much is Novasenta worth (valuation)?

Valuation information for Novasenta is not publicly available.

Can I buy Novasenta stock?

Novasenta shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Novasenta's last funding round?

Novasenta's most recent funding round was Series A on July 29, 2022.

Who are the main investors in Novasenta?

Key investors in Novasenta include UPMC, UPMC Enterprises.

Will Novasenta IPO soon?

No public IPO plans have been announced for Novasenta.

How can I track Novasenta secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Novasenta's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPittsburgh, Pennsylvania
Employee Range15
Year Founded2018
Last FundingFeb 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?